Anbio Biotechnology cash flow statement NNNN

Annual Quarterly

In fiscal 2025, which ended Dec 31, 2025, Anbio Biotechnology used $6.7 million of cash from operations, down 423.9% from the year before.

USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.

Line
FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
Operating
Operating cash flow
-7
-423.9%
2
Investing
Investing cash flow
-4
-1346.7%
0
Financing
Financing cash flow
7
+2116.1%
-0
Ratios
Cash conversion
-1.05x
0.88x
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.

Company profile

Industry
In Vitro & In Vivo Diagnostic Substances (SIC 2835)
Listed as
NNNN (Nasdaq)
Fiscal year ends
December 31
Incorporated in
Cayman Islands
Headquarters
Frankfurt Am Main, Germany
SEC filer status
Non-accelerated filer, Emerging growth company
SEC CIK
1982708

Other In Vitro & In Vivo Diagnostic Substances companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.